ECOSPOR II: An Expanded Access for Intermediate-size Patient Population and Open-Label Extension of Study SERES-004 to Evaluate SER-109 in Patients With Recurrent Clostridium Difficile Infection

Trial Profile

ECOSPOR II: An Expanded Access for Intermediate-size Patient Population and Open-Label Extension of Study SERES-004 to Evaluate SER-109 in Patients With Recurrent Clostridium Difficile Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs SER 109 (Primary)
  • Indications Clostridium infections
  • Focus Expanded access; Therapeutic Use
  • Acronyms ECOSPOR II
  • Sponsors Seres Therapeutics
  • Most Recent Events

    • 31 Jan 2017 Results from this and a parent study (ECOSPOR) published in a Seres Therapeutics media release.
    • 30 Jan 2017 According to Seres Therapeutics media release, company will host a conference call and live audio webcast to discuss results from this and ECOSPOR study.
    • 16 Nov 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top